Are ICER Threshold Values Malleable? The Case of Life-Extending Cancer Treatments at the End of Life

Moïse, Pierre; Sweeney, Nathan W.; Lie, X.

doi:10.1016/j.jval.2013.08.582

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incremental costs coupled with QALY gains yielded incremental cost-effectiveness ratios (ICERs) for once-weekly semaglutide 1 mg versus canagliflozin 300 mg of CAD16,392 (IHE-DCM) and CAD18,098 (ECHO-T2DM) per QALY gained from a healthcare payer perspective, and CAD14,127 (IHE-DCM) and CAD13,188 (ECHO-T2DM) per QALY gained from a broader societal perspective (Table 2 ). Each of these estimated ICERs falls below the commonly used Canadian willingness-to-pay (WTP) threshold of CAD50,000 per QALY gained [ 44 , 45 ].…”

Section: Resultsmentioning

confidence: 99%

Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting

Stafford

Bech²,

Fridhammar

et al. 2022

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Objective Our objective was to evaluate the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus once-daily canagliflozin 300 mg in patients with type 2 diabetes mellitus (T2DM) uncontrolled with metformin from the healthcare payer and societal perspectives in Canada. Methods Head-to-head data from the SUSTAIN 8 randomised trial (NCT03136484) were extrapolated over 40 years using economic simulation modelling. The cost-effectiveness of once-weekly semaglutide 1 mg versus canagliflozin 300 mg for treating T2DM was estimated using the Swedish Institute for Health Economics-Diabetes Cohort Model (IHE-DCM) and the Economic and Health Outcomes Model of T2DM (ECHO-T2DM). Unit costs and disutility weights capturing treatments and key macro- and microvascular complications were sourced from the literature to best match the Canadian setting. A probabilistic base-case simulation and sensitivity analyses were conducted. Results Once-weekly semaglutide 1 mg was associated with reductions in macro- and microvascular complications, yielding incremental cost-effectiveness ratios (ICERs) of (Canadian dollars [CAD]) CAD16,392 and 18,098 per incremental quality-adjusted life-year (QALY) gained versus canagliflozin 300 mg for IHE-DCM and ECHO-T2DM, respectively, from a healthcare payer perspective. Accounting for productivity loss as well, ICERs were CAD14,127 and 13,188 per QALY gained for IHE-DCM and ECHO-T2DM, respectively, from a societal perspective. Sensitivity analyses confirmed that the base-case results were robust to changes in input parameters and assumptions used. Conclusions At a willingness-to-pay threshold of CAD50,000 per QALY gained, once-weekly semaglutide 1 mg was cost-effective over 40 years versus once-daily canagliflozin 300 mg for the treatment of T2DM in patients failing to maintain glycemic control with metformin alone. Supplementary Information The online version contains supplementary material available at 10.1007/s40258-022-00726-z.

show abstract

Section: Resultsmentioning

confidence: 99%